The Bleeding Risk in Antithrombotic Therapies: A Narrative Review

Adriano       Alatri; Lucia       Mazzolai
Abstract

Bleeding represents the most important complication of antithrombotic treatment, including anticoagulant and antiplatelet therapies. A number of scores were proposed to evaluate the risk of bleeding both for anticoagulant and antiplatelet treatment. In the last decade, 5 bleeding risk scores were published for use in atrial fibrillation patients, and 3 scores for patients receiving anticoagulants for venous thromboembolism therapy or prophylaxis. In addition, 3 scores were recently developed to assess inhospital or short-term bleeding risk in patients receiving antiplatelet therapy after Acute Coronary Syndrome (ACS) and Percutaneous Coronary Intervention (PCI). Furthermore, 3 additional scores have focused on long-term bleeding in outpatients receiving dual antiplatelet therapy after PCI. The aim of this review is to consider the evidence on bleeding scores.
Keywords: Bleeding, clinical predictive rules, atrial fibrillation, venous thromboembolism, acute coronary syndrome, percutaneous coronary intervention, anticoagulants, antiplatelet therapy.
Graphical Abstract

[1] 
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost  2005; 3(4): 692-4.
[http://dx.doi.org/10.1111/j.1538-7836.2005.01204.x] [PMID: 15842354] 
[2] 
Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost  2015; 13(11): 2119-26.
[http://dx.doi.org/10.1111/jth.13140] [PMID: 26764429] 
[3] 
Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation  2011; 123(23): 2736-47.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.009449] [PMID: 21670242] 
[4] 
Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med  1989; 87(2): 144-52.
[http://dx.doi.org/10.1016/S0002-9343(89)80689-8] [PMID: 2787958] 
[5] 
Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med  1998; 105(2): 91-9.
[http://dx.doi.org/10.1016/S0002-9343(98)00198-3] [PMID: 9727814] 
[6] 
Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med  2003; 163(8): 917-20.
[http://dx.doi.org/10.1001/archinte.163.8.917] [PMID: 12719200] 
[7] 
Aspinall SL, DeSanzo BE, Trilli LE, Good CB. Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med  2005; 20(11): 1008-13.
[http://dx.doi.org/10.1111/j.1525-1497.2005.0229.x] [PMID: 16307625] 
[8] 
Kuijer PM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med  1999; 159(5): 457-60.
[http://dx.doi.org/10.1001/archinte.159.5.457] [PMID: 10074953] 
[9] 
Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med  2003; 349(7): 631-9.
[http://dx.doi.org/10.1056/NEJMoa035422] [PMID: 12917299] 
[10] 
Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest  2006; 130(5): 1390-6.
[http://dx.doi.org/10.1378/chest.130.5.1390] [PMID: 17099015] 
[11] 
Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J  2006; 151(3): 713-9.
[http://dx.doi.org/10.1016/j.ahj.2005.04.017] [PMID: 16504638] 
[12] 
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest  2010; 138(5): 1093-100.
[http://dx.doi.org/10.1378/chest.10-0134] [PMID: 20299623] 
[13] 
Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol  2011; 58(4): 395-401.
[http://dx.doi.org/10.1016/j.jacc.2011.03.031] [PMID: 21757117] 
[14] 
O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J  2015; 36(46): 3258-64.
[http://dx.doi.org/10.1093/eurheartj/ehv476] [PMID: 26424865] 
[15] 
Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet  2016; 387(10035): 2302-11.
[http://dx.doi.org/10.1016/S0140-6736(16)00741-8] [PMID: 27056738] 
[16] 
Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost  2008; 100(1): 26-31.
[http://dx.doi.org/10.1160/TH08-03-0193] [PMID: 18612534] 
[17] 
Nieto JA, Solano R, Ruiz-Ribó MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost  2010; 8(6): 1216-22.
[http://dx.doi.org/10.1111/j.1538-7836.2010.03852.x] [PMID: 20345727] 
[18] 
Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest  2011; 139(1): 69-79.
[http://dx.doi.org/10.1378/chest.09-3081] [PMID: 20453069] 
[19] 
Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost  2011; 9(8): 1460-7.
[http://dx.doi.org/10.1111/j.1538-7836.2011.04378.x] [PMID: 21624047] 
[20] 
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J  2012; 33(12): 1500-10.
[http://dx.doi.org/10.1093/eurheartj/ehr488] [PMID: 22246443] 
[21] 
Gallego P, Roldán V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol  2012; 5(2): 312-8.
[http://dx.doi.org/10.1161/CIRCEP.111.967000] [PMID: 22319005] 
[22] 
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol  2011; 57(2): 173-80.
[http://dx.doi.org/10.1016/j.jacc.2010.09.024] [PMID: 21111555] 
[23] 
Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol  2012; 60(9): 861-7.
[http://dx.doi.org/10.1016/j.jacc.2012.06.019] [PMID: 22858389] 
[24] 
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med  2011; 365(10): 883-91.
[http://dx.doi.org/10.1056/NEJMoa1009638] [PMID: 21830957] 
[25] 
Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin. Am J Med  2016; 129(6): 600-7.
[http://dx.doi.org/10.1016/j.amjmed.2015.10.001] [PMID: 26482233] 
[26] 
Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol  2014; 40(3): 277-84.
[http://dx.doi.org/10.1007/s10840-014-9930-y] [PMID: 25012972] 
[27] 
Zhu W, He W, Guo L, Wang X, Hong K. the has-bled score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol  2015; 38(9): 555-61.
[http://dx.doi.org/10.1002/clc.22435] [PMID: 26418409] 
[28] 
Fauchier L, Chaize G, Gaudin A-F, Vainchtock A, Rushton-Smith SK, Cotté FE. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. Int J Cardiol  2016; 217: 85-91.
[http://dx.doi.org/10.1016/j.ijcard.2016.04.173] [PMID: 27179213] 
[29] 
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med  2011; 365(11): 981-92.
[http://dx.doi.org/10.1056/NEJMoa1107039] [PMID: 21870978] 
[30] 
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med  2009; 361(12): 1139-51.
[http://dx.doi.org/10.1056/NEJMoa0905561] [PMID: 19717844] 
[31] 
Zulkifly H, Lip GYH, Lane DA. bleeding risk scores in atrial fibrillation and venous thromboembolism. Am J Cardiol  2017; 120(7): 1139-45.
[http://dx.doi.org/10.1016/j.amjcard.2017.06.058] [PMID: 28800833] 
[32] 
Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost  2017; 117(10): 1848-58.
[http://dx.doi.org/10.1160/TH17-07-0478] [PMID: 28799620] 
[33] 
Nieto JA, Solano R, Trapero Iglesias N, et al. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thromb Res  2013; 132(2): 175-9.
[http://dx.doi.org/10.1016/j.thromres.2013.06.019] [PMID: 23849097] 
[34] 
Hostler DC, Marx ES, Moores LK, et al. Validation of the international medical prevention registry on venous thromboembolism bleeding risk score. Chest  2016; 149(2): 372-9.
[http://dx.doi.org/10.1378/chest.14-2842] [PMID: 26867833] 
[35] 
Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation  2006; 114(8): 774-82.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.612812] [PMID: 16908769] 
[36] 
Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol  2007; 49(12): 1362-8.
[http://dx.doi.org/10.1016/j.jacc.2007.02.027] [PMID: 17394970] 
[37] 
Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation  2009; 119(14): 1873-82.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.828541] [PMID: 19332461] 
[38] 
Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol  2010; 55(23): 2556-66.
[http://dx.doi.org/10.1016/j.jacc.2009.09.076] [PMID: 20513595] 
[39] 
Mathews R, Peterson ED, Chen AY, et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. Am J Cardiol  2011; 107(8): 1136-43.
[http://dx.doi.org/10.1016/j.amjcard.2010.12.009] [PMID: 21324428] 
[40] 
Yeh RW, Secemsky EA, Kereiakes DJ, et al. development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA  2016; 315(16): 1735-49.
[http://dx.doi.org/10.1001/jama.2016.3775] [PMID: 27022822] 
[41] 
Baber U, Mehran R, Giustino G, et al. Coronary thrombosis and major bleeding after pci with drug-eluting stents: risk scores from paris. J Am Coll Cardiol  2016; 67(19): 2224-34.
[http://dx.doi.org/10.1016/j.jacc.2016.02.064] [PMID: 27079334] 
[42] 
Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet  2017; 389(10073): 1025-34.
[http://dx.doi.org/10.1016/S0140-6736(17)30397-5] [PMID: 28290994] 
[43] 
Abu-Assi E, Gracía-Acuña JM, Ferreira-González I, Peña-Gil C, Gayoso-Diz P, González-Juanatey JR. Evaluating the performance of the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA Guidelines (CRUSADE) bleeding score in a contemporary Spanish cohort of patients with non-ST-segment elevation acute myocardial infarction. Circulation  2010; 121(22): 2419-26.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.925594] [PMID: 20497978] 
[44] 
Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J  2004; 148(5): 764-75.
[http://dx.doi.org/10.1016/j.ahj.2004.04.036] [PMID: 15523305] 
[45] 
Mehran R, Brodie B, Cox DA, et al. The harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J  2008; 156(1): 44-56.
[http://dx.doi.org/10.1016/j.ahj.2008.02.008] [PMID: 18585496] 
[46] 
Desai NR, Kennedy KF, Cohen DJ, et al. Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry®-Get With The Guidelines (GWTG)®. Am Heart J  2017; 194: 16-24.
[http://dx.doi.org/10.1016/j.ahj.2017.08.004] [PMID: 29223432] 
[47] 
Flores-Ríos X, Couto-Mallón D, Rodríguez-Garrido J, et al. Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding risk scores in STEMI undergoing primary PCI: insights from a cohort of 1391 patients. Eur Heart J Acute Cardiovasc Care  2013; 2(1): 19-26.
[http://dx.doi.org/10.1177/2048872612469885] [PMID: 24062930] 
[48] 
Liu R, Lyu SZ, Zhao GQ, et al. Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding scores in ACS patients undergoing PCI: insights from a cohort of 4939 patients in China. J Geriatr Cardiol  2017; 14(2): 93-9.
[PMID: 28491083] 
[49] 
Xi S, Zhou S, Wang X, et al. The Performance of CRUSADE and ACUITY bleeding risk scores in ticagrelor-treated ACS patients who underwent PCI. Thromb Haemost  2017; 117(11): 2186-93.
[http://dx.doi.org/10.1160/TH17-04-0237] [PMID: 29044298] 
[50] 
Bittl JA, Baber U, Bradley SM, Wijeysundera DN. duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol  2016; 68(10): 1116-39.
[http://dx.doi.org/10.1016/j.jacc.2016.03.512] [PMID: 27036919] 
[51] 
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol  2016; 68(10): 1082-115.
[http://dx.doi.org/10.1016/j.jacc.2016.03.513] [PMID: 27036918] 
[52] 
Valgimigli M, Bueno H, Byrne RA, et al. ESC focused update on dual
antiplatelet therapy in coronary artery disease developed in collaboration
with EACTS: The task force for dual antiplatelet therapy in coronary
artery disease of the European society of cardiology (ESC) and of
the European association for cardio-thoracic surgery (EACTS). Eur Heart J  2018; 39(3): 213-60.
[http://dx.doi.org/10.1093/eurheartj/ehx419] [PMID: 28886622] 
[53] 
Costa F, Tijssen JG, Ariotti S, et al. Incremental Value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy. J Am Heart Assoc  2015; 4 pii: e002524
[http://dx.doi.org/10.1161/JAHA.115.002524] [PMID: 26643501] 
[54] 
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J  2016; 37: 2893-962.
[http://dx.doi.org/10.1093/eurheartj/ehw210] [PMID: 27567408] 
Cite As
Current Vascular Pharmacology

The Bleeding Risk in Antithrombotic Therapies: A Narrative Review

Abstract

Graphical Abstract
